These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 34392358)
1. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike? Volpe M; Gallo G Eur Heart J; 2021 Sep; 42(36):3753-3755. PubMed ID: 34392358 [No Abstract] [Full Text] [Related]
3. [Sacubitril-valsartan should also be the first choice to be evaluated in the elderly patient with heart failure with reduced ejection fraction]. Camafort M; Formiga F Rev Esp Geriatr Gerontol; 2021; 56(2):67-68. PubMed ID: 33526274 [No Abstract] [Full Text] [Related]
4. No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction. Slawson DC Am Fam Physician; 2022 Jun; 105(6):Online. PubMed ID: 35704816 [No Abstract] [Full Text] [Related]
5. Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? McMurray JJV Kardiol Pol; 2021 Jan; 79(1):104-105. PubMed ID: 33427436 [No Abstract] [Full Text] [Related]
6. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy. Crea F Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264 [No Abstract] [Full Text] [Related]
7. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function. Voordes GHD; Heerspink HJL; Ter Maaten JM Eur J Heart Fail; 2022 May; 24(5):804-806. PubMed ID: 35415946 [No Abstract] [Full Text] [Related]
8. Sacubitril/valsartan-A new weapon for fighting the hypertension paradox. Ohishi M Hypertens Res; 2022 May; 45(5):915-916. PubMed ID: 35273352 [No Abstract] [Full Text] [Related]
9. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508 [No Abstract] [Full Text] [Related]
10. [Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension]. Lozhkina NG; Spiridonov AN Kardiologiia; 2022 May; 62(5):72-74. PubMed ID: 35692177 [TBL] [Abstract][Full Text] [Related]
11. Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye? Sinha A; Patel RB Eur J Heart Fail; 2023 Jan; 25(1):95-97. PubMed ID: 36445011 [No Abstract] [Full Text] [Related]
12. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Kario K Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807 [TBL] [Abstract][Full Text] [Related]
13. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction. Antol DD; Casebeer AW; DeClue RW; Stemkowski S; Russo PA Adv Ther; 2018 Jun; 35(6):785-795. PubMed ID: 29777521 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS; Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237 [TBL] [Abstract][Full Text] [Related]
16. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety. Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344 [TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Author's reply. Lelonek M Kardiol Pol; 2021 Jan; 79(1):105. PubMed ID: 33427437 [No Abstract] [Full Text] [Related]
19. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412 [TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]